ATAI Life Sciences B.V.*(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ATAI ATAI Life Sciences B.V.*

休市中 10-24 16:00:00 EDT

5.77

+0.22

+3.96%

盘后5.76

-0.01-0.17%

19:57 EDT

最高5.94	最低5.72	成交量459.67万
今开5.85	昨收5.55	日振幅3.96%
总市值15.18亿	流通市值12.06亿	总股本2.63亿
成交额2,673万	换手率2.20%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ATAI","market":"US","secType":"STK","nameCN":"ATAI Life Sciences B.V.*","latestPrice":5.77,"timestamp":1761336000000,"preClose":5.55,"halted":0,"volume":4596721,"hourTrading":{"tag":"盘后","latestPrice":5.76,"preClose":5.77,"latestTime":"19:57 EDT","volume":44837,"amount":258604.6296,"timestamp":1761350221613},"delay":0,"floatShares":209000000,"shares":263000000,"eps":-0.68791,"marketStatus":"休市中","change":0.22,"latestTime":"10-24 16:00:00 EDT","open":5.85,"high":5.94,"low":5.72,"amount":26726754.442100603,"amplitude":0.03964,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.68791,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1761552000000},"marketStatusCode":7,"adr":1,"adrRate":2,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":5.55,"preHourTrading":{"tag":"盘前","latestPrice":5.84,"preClose":5.55,"latestTime":"09:29 EDT","volume":89928,"amount":517054.165488,"timestamp":1761312570055},"postHourTrading":{"tag":"盘后","latestPrice":5.76,"preClose":5.77,"latestTime":"19:57 EDT","volume":44837,"amount":258604.6296,"timestamp":1761350221613},"volumeRatio":0.38533003043015596,"impliedVol":1.024,"impliedVolPercentile":0.296},"requestUrl":"/m/hq/s/ATAI","defaultTab":"news","newsList":[{"id":"2578449075","title":"ATAI Life Sciences Shares Rise After Berenberg Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2578449075","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578449075?lang=zh_cn&edition=full","pubTime":"2025-10-25 02:37","pubTimestamp":1761331062,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences  shares were up 3.4% in recent Friday trading after Berenberg upgraded its rating on the drugmaker's stock to buy from positive, with a $12 price target.Intraday volume was over 3.6 million shares, compared with the daily average of about 6.4 million.Price: 5.74, Change: +0.19, Percent Change: +3.42","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"贝伦贝格升级后ATAI Life Sciences股价上涨","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATAI"],"gpt_icon":0},{"id":"2577518639","title":"Berenberg Upgrades ATAI Life Sciences to Buy From Positive, Price Target is $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2577518639","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577518639?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:25","pubTimestamp":1761305137,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences (ATAI) has an average rating of buy and mean price target of $12.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"Berenberg将ATAI Life Sciences评级从正面上调至买入，目标价为12美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATAI"],"gpt_icon":0},{"id":"2577994048","title":"Atai Life Sciences Raises $149.5 Million From Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2577994048","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577994048?lang=zh_cn&edition=full","pubTime":"2025-10-21 06:04","pubTimestamp":1760997840,"startTime":"0","endTime":"0","summary":"Atai Life Sciences  said late Monday it has closed its public offering of around 27.3 million shares, including the full exercise of an over-allotment option, raising about $149.5 million.The clinical-stage biopharmaceutical company said it expects its funds will be sufficient to cover its operations into 2029.Shares of the company were up about 2% in after-hours activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Atai Life Sciences通过公开发行筹集1.495亿美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","ATAI"],"gpt_icon":0},{"id":"1198999615","title":"ATAI Life Sciences NV以每股5.48美元定价2370万股股票发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1198999615","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198999615?lang=zh_cn&edition=full","pubTime":"2025-10-17 10:43","pubTimestamp":1760669005,"startTime":"0","endTime":"0","summary":"10月17日消息 - ATAI Life Sciences NV宣布，已以每股5.48美元的价格，成功定价2372.5万股普通股的注册承销发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATAI","BK4539"],"gpt_icon":0},{"id":"2575406175","title":"Needham Initiates ATAI Life Sciences N.V at Buy With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2575406175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575406175?lang=zh_cn&edition=full","pubTime":"2025-10-13 20:24","pubTimestamp":1760358262,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences N.V (ATAI) has an average rating of buy and mean price target of $11.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"Needham对ATAI Life Sciences N.V给予买入评级，目标价为12美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATAI"],"gpt_icon":0},{"id":"2568433470","title":"Atai Life Sciences Wins $11.4 Million Grant From National Institutes of Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2568433470","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568433470?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:08","pubTimestamp":1758200932,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences  said Thursday it was awarded a multi-year, milestone-driven grant worth up to $11.4 million by the National Institute on Drug Abuse, under the National Institutes of Health.The grant will provide non-dilutive funding to advance Atai Life Sciences' 5-HT2A/2C receptor agonist program, which aims to develop novel compounds that will modulate serotonin receptors implicated in addiction, the company said.Shares of the company were up nearly 3% in recent Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Atai Life Sciences获得美国国立卫生研究院1140万美元资助","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","ATAI","BK4007","NHLD"],"gpt_icon":0},{"id":"2559951300","title":"ATAI Life Sciences Q2 EPS $(0.14) Misses $(0.12) Estimate, Sales $719.000K Up From $273.000K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2559951300","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559951300?lang=zh_cn&edition=full","pubTime":"2025-08-14 19:17","pubTimestamp":1755170222,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 61.11 percent increase over losses of $(0.36) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"ATAI Life Sciences第二季度EPS$(0.14)低于$(0.12)预期，销售额从去年同期的273,000 K美元增至719,000 K美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47117724/atai-life-sciences-q2-eps-0-14-misses-0-12-estimate-sales-719-000k-up-from-273-000k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI"],"gpt_icon":0},{"id":"2559590949","title":"Earnings Flash (ATAI) Atai Life Sciences Posts Q2 Net Loss $0.14 a Share, vs. FactSet Est of $0.11 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2559590949","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559590949?lang=zh_cn&edition=full","pubTime":"2025-08-14 19:07","pubTimestamp":1755169655,"startTime":"0","endTime":"0","summary":"Earnings Flash (ATAI) Atai Life Sciences Posts Q2 Net Loss $0.14 a Share, vs. FactSet Est of $0.11 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"财报(ATAI)Atai Life Sciences公布第二季度每股净亏损0.14美元，而FactSet预计亏损0.11美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATAI"],"gpt_icon":0},{"id":"2554798357","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2554798357","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554798357?lang=zh_cn&edition=full","pubTime":"2025-07-28 19:46","pubTimestamp":1753703211,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences  shares were 10% lower pre-bell Monday after saying Friday that its phase 2b trial of inidascamine in patients with cognitive impairment associated with schizophrenia failed to achieve its primary endpoint.Kazia Therapeutics  stock was down 10% following a 1.4% loss in the previous session.Linkhome Holdings  shares were 9.3% lower, paring Friday's 83% rally.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"盘前跌幅最大的股票","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","ATAI","KZIA","BK4139"],"gpt_icon":0},{"id":"2536261263","title":"Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2536261263","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536261263?lang=zh_cn&edition=full","pubTime":"2025-05-20 20:04","pubTimestamp":1747742679,"startTime":"0","endTime":"0","summary":"Atai Life Sciences  said Tuesday that topline data from a phase 2a trial showed that a single dose of its drug BPL-003, when given to patients who were also taking defined selective serotonin reuptake inhibitors, produced antidepressive effects of up to three months.The drug was well-tolerated with no serious adverse events, and an average in-clinic treatment time following dosing of less than two hours, the company said.The 12-patient study showed average MADRS score reductions of 18 to 19 points up to three months post-treatment, supporting prior monotherapy findings, Atai said.Atai shares were 3.8% lower in recent premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Atai Life Sciences报告难治性抑郁症药物2a期结果积极","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ATAI","BK4539"],"gpt_icon":0},{"id":"2535026033","title":"ATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M","url":"https://stock-news.laohu8.com/highlight/detail?id=2535026033","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535026033?lang=zh_cn&edition=full","pubTime":"2025-05-14 20:21","pubTimestamp":1747225260,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 11.76 percent increase over losses of $(0.17) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"ATAI Life Sciences第一季度EPS$(0.15)超出预期$(0.18)，销售额155万美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45404379/atai-life-sciences-q1-eps-0-15-beats-0-18-estimate-sales-1-55m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atai.life","stockEarnings":[{"period":"1week","weight":-0.1054},{"period":"1month","weight":0.051},{"period":"3month","weight":0.6162},{"period":"6month","weight":2.9521},{"period":"1year","weight":4.0614},{"period":"ytd","weight":3.3383}],"compareEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":0.0244},{"period":"3month","weight":0.063},{"period":"6month","weight":0.2299},{"period":"1year","weight":0.1692},{"period":"ytd","weight":0.1556}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ATAI Life Sciences N.V.于2020年9月10日根据荷兰法律注册为Adripa Holding B.V.。2021年1月11日，更名为ATAI Life Sciences B.V.。他们是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方法。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.051111},{"month":2,"riseRate":0.75,"avgChangeRate":0.055077},{"month":3,"riseRate":0.5,"avgChangeRate":-0.057424},{"month":4,"riseRate":0.75,"avgChangeRate":0.001524},{"month":5,"riseRate":0.25,"avgChangeRate":0.04946},{"month":6,"riseRate":0,"avgChangeRate":-0.082337},{"month":7,"riseRate":0.8,"avgChangeRate":0.230191},{"month":8,"riseRate":0.6,"avgChangeRate":-0.017917},{"month":9,"riseRate":0.2,"avgChangeRate":-0.094209},{"month":10,"riseRate":0.2,"avgChangeRate":-0.032853},{"month":11,"riseRate":0.5,"avgChangeRate":0.118488},{"month":12,"riseRate":0.25,"avgChangeRate":-0.11215}],"exchange":"NASDAQ","name":"ATAI Life Sciences B.V.*","nameEN":"ATAI Life Sciences B.V.*"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.4","shortVersion":"4.35.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATAI Life Sciences B.V.*(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ATAI Life Sciences B.V.*(ATAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ATAI Life Sciences B.V.*,ATAI,ATAI Life Sciences B.V.*股票,ATAI Life Sciences B.V.*股票老虎,ATAI Life Sciences B.V.*股票老虎国际,ATAI Life Sciences B.V.*行情,ATAI Life Sciences B.V.*股票行情,ATAI Life Sciences B.V.*股价,ATAI Life Sciences B.V.*股市,ATAI Life Sciences B.V.*股票价格,ATAI Life Sciences B.V.*股票交易,ATAI Life Sciences B.V.*股票购买,ATAI Life Sciences B.V.*股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATAI Life Sciences B.V.*(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ATAI Life Sciences B.V.*(ATAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况